Corcept Stock Plunge: Insider Sale or Buying Opportunity?

Corcept Therapeutics' stock plummeted after its Chief Development Officer sold a massive chunk of his shares for $1.8 million, sparking investor concern despite a pre-planned sale. While the company recently announced a partnership to improve patient support for Cushing's syndrome and is developing a new drug, relacorilant, to diversify its revenue, the insider sale overshadowed these positive developments. Despite the drop, Corcept's stock is still up 50% for the year, highlighting the volatile but potentially rewarding nature of biopharma investments. Hosted on Acast. See acast.com/privacy for more information.